Reaction
Nail Toxicity reporting signals
As of the last recalculation, Nail Toxicity appears in 294 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is PERTUZUMAB (PRR 113.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pertuzumab | 38 | 113.5 | 113.7 |
| Docetaxel Anhydrous | 63 | 84.0 | 84.0 |
| Docetaxel | 63 | 84.0 | 84.0 |
| Trastuzumab | 55 | 69.6 | 69.6 |
| Paclitaxel (Aibumin-Bound) | 63 | 68.8 | 68.8 |
| Paclitaxel | 71 | 66.6 | 66.6 |
| Ado-Trastuzumab Emtansine | 4 | 34.0 | 34.1 |
| Panitumumab | 7 | 32.4 | 32.4 |
| Cetuximab | 10 | 23.4 | 23.4 |
| Osimertinib | 8 | 18.1 | 18.1 |